Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACTG A5202: EFV or ATV/r with FTC/TDF or ABC/3TC in Naive HIV
NCT00118898Phase 3Completed
- Start
- Sep 2005
- Primary completion
- Nov 2009
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of atazanavir, emtricitabine + tenofovir disoproxil and abacavir + lamivudine in human immunodeficiency virus infection (HIV) (4 arms). Primary endpoints: Time From Randomization to Virologic Failure at 138 weeks, Time From Treatment Dispensation to a Grade 3/4 Safety Event at 120 weeks and 1 more. Started Sep 2005; status: completed.
02
Drugs
atazanaviremtricitabine + tenofovir disoproxilabacavir + lamivudine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00118898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00118898.